FIELD: medicine.
SUBSTANCE: there are disclosed polypeptide variants containing Fc-areas IgG, having amino acid modifications providing changed effector functions Fc in specified polypeptides. There is disclosed composition for antibody targeting on antigen, containing the specified polypeptide. There is described method for preparing the specified polypeptide. Also, there are disclosed the methods for treating V-cell tumour or a malignant disease characterised by V-cell expression of CD20, treating chronic lymphocytic leukosis, relieving the symptoms of the V-cell controlled autoimmune disease, treating a angiogenesis-associated disorder, treating HER2-expressing cancer, treating LFA-1-mediated involvement, treating IgE-mediated involvement wherein specified methods imply introduction to the patient of the therapeutically effective amount of said polypeptide.
EFFECT: higher clinical effectiveness.
63 cl, 6 ex, 13 dwg, 10 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| ANTIBODY Fc VARIANTS | 2012 |
|
RU2607014C2 |
| VERSIONS OF IMMUNOGLOBULIN AND THEIR APPLICATION | 2009 |
|
RU2536937C2 |
| METHOD FOR SELECTION AND OBTAINING OF HIGHLY SELECTIVE AND MULTISPECIFIC TARGETING GROUPS WITH SPECIFIED PROPERTIES, INCLUDING AT LEAST TWO DIFFERENT BINDING GROUPS, AND THEIR APPLICATIONS | 2013 |
|
RU2639287C2 |
| ADVANCED ANTIBODY MOLECULES | 2009 |
|
RU2430111C1 |
| APPLICATION OF ANTI-CD40-ANTIBODIES | 2006 |
|
RU2442606C2 |
| IN VITRO PREDICTION OF ANTIBODY HALF-LIFE IN VIVO | 2015 |
|
RU2688349C2 |
| Fc-RECEPTOR BINDING MODIFIED ASYMMETRIC ANTIBODIES AND METHODS OF USE | 2014 |
|
RU2687043C2 |
| NOVEL ANTIBODIES | 2008 |
|
RU2490277C2 |
| DLL4 ANTIBODIES AND METHODS OF APPLICATION THEREOF | 2007 |
|
RU2415869C2 |
| PURIFICATION OF ANTIBODIES WITH CATION-EXCHANGE CHROMATOGRAPHY | 2008 |
|
RU2498991C2 |
